Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease.
about
ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cellsRedox-directed cancer therapeutics: molecular mechanisms and opportunitiesA conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma CareChemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cellsReversing the intractable nature of pancreatic cancer by selectively targeting ALDH-high, therapy-resistant cancer cellsAn image-based, high-throughput screening assay for molecules that induce excess DNA replication in human cancer cellsHigh-throughput screening for genes that prevent excess DNA replication in human cells and for molecules that inhibit themLiposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells in vitro and in vivo.High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells.Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells.Antitubercular activity of disulfiram, an antialcoholism drug, against multidrug- and extensively drug-resistant Mycobacterium tuberculosis isolates.Degradation of NF-κB, p53 and other regulatory redox-sensitive proteins by thiol-conjugating and -nitrosylating drugs in human tumor cells.New applications of old metal-binding drugs in the treatment of human cancer.Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells.Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells.Honokiol is a potent scavenger of superoxide and peroxyl radicals.The chemistry of cell signaling by reactive oxygen and nitrogen species and 4-hydroxynonenal.Clinical development of novel proteasome inhibitors for cancer treatment.Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells.Clustering drug-drug interaction networks with energy model layouts: community analysis and drug repurposing.Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution.Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage.Effective elimination of adult B-lineage acute lymphoblastic leukemia by disulfiram/copper complex in vitro and in vivo in patient-derived xenograft models.Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells.Antileishmanial Activity of Disulfiram and Thiuram Disulfide Analogs in an Ex Vivo Model System Is Selectively Enhanced by the Addition of Divalent Metal Ions.Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.Copper signaling axis as a target for prostate cancer therapeutics.Vaginal drug delivery for the localised treatment of cervical cancer.Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.Stimulation of the alveolar macrophage respiratory burst by ADP causes selective glutathionylation of protein tyrosine phosphatase 1B.Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition.Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly.Hydroxycobalamin catalyzes the oxidation of diethyldithiocarbamate and increases its cytotoxicity independently of copper ionsDiscovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition
P2860
Q24569826-0E0AE5E4-AFAE-4A23-9AFD-1BB85372327FQ24645584-6E47E732-5979-49AB-ADBF-53DDF3E116A8Q26851160-8EFCC3B7-2869-43DF-AE3B-23BD05D5AAF0Q28484299-E406A4D8-CE51-4DAD-A69A-6E423B955D05Q28534611-05D558D9-E738-4C4C-BA6E-6B3472E26D56Q33800817-4BADD8CE-DE1D-464F-B468-E9E45377786DQ34111180-B55DDA53-68C1-4974-A7E5-56AA96D1E9F2Q34365729-9D57DA6F-83D1-4859-B9D6-859F49FC4C07Q34481639-ADD9A59D-D8A7-4198-A53B-2BAF92A2EF57Q35054730-1E3DFE3F-08C8-4B8D-B03B-A47FAE8AAFA8Q36171517-026D1504-BCE2-4667-9A5C-C75E543B1D5EQ36814016-15972D48-54B5-42A2-B023-33D1B42D148FQ36822739-CFBD00DC-36EB-4C02-9FEE-A5E4B24FF333Q36837031-0FE1A489-0CAF-4657-BE43-79816101C9D9Q36953350-23796CF8-ECE1-4D61-B0CD-552CC507CF05Q36954777-C06A1DD4-074C-4DED-B331-2B1B87E1E458Q36990410-E39CA43D-24F6-4EC3-A358-8A9F66C08A1BQ37136598-B2A2AFDF-4817-4572-AF90-5FADA023D5DFQ37214346-8120F46D-0763-420B-856E-F5E6080D2229Q37236776-5226D992-7D8B-4EFE-8254-0942FABBF1FEQ37392908-F8E3F6FF-F10D-45F1-B27D-675459D62BFBQ37616054-A1C5F259-92E7-4DCF-99E6-9B123D2DEA8EQ37696104-7C48A3BF-02E3-4A29-ADA3-FE717311F60EQ37719254-F2773127-0954-4EF0-9FE9-2CC567A293ACQ38406751-38F8205E-5592-4E56-9C88-7ABDAD2CEE80Q38777221-3517012F-CC71-4D54-984D-A4C3140B8BC4Q38947366-AF4487A4-1A08-4D98-B4B7-97758D282BA8Q39361267-7F2C56D1-0D4C-4DCE-AB56-50BDFB8DF58BQ39660971-8BB2BE43-29BD-430E-B2F8-A6A4A51C16E0Q40266375-B2BE1F18-E3AA-4AE6-B4D5-23B9617DF80FQ41082509-7780B01D-D8EF-49C3-8385-DEDAE728EB0CQ41575123-ADE943F4-0A93-4C31-8006-0F3C34741F3CQ51768249-C892377C-F713-4621-B610-FAD73585F74CQ57070043-17EA101E-588D-4D33-BBB3-B70E17201CA7Q57163862-6D6B91FC-073A-4BB4-942B-981863D46301
P2860
Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Disulfiram inhibits activating ...... tient with metastatic disease.
@en
type
label
Disulfiram inhibits activating ...... tient with metastatic disease.
@en
prefLabel
Disulfiram inhibits activating ...... tient with metastatic disease.
@en
P2093
P1476
Disulfiram inhibits activating ...... atient with metastatic disease
@en
P2093
A Richard Whorton
Andrew J Ghio
Catherine Austin
Claude Grigg
David P White
Didier Dreau
Grayson W Stowell
Kimberly S Wilson
Linda B Whittall
Mareva Foster
P304
P577
2004-09-01T00:00:00Z